Limitations in pancreatic enzyme replacement therapy (PERT) can cause patients with EPI to fall through the cracks
Limitations in pancreatic enzyme replacement therapy (PERT)
can cause patients with EPI
to
fall
through the cracks
EPI=exocrine pancreatic insufficiency.
EPI=exocrine pancreatic insufficiency.
*Analysis of MMIT coverage data includes commercial, Medicare, Medicaid, and health insurance exchange lives with coverage status of "covered" or better. Coverage data are based on publicly available plan-level data and may not reflect individual patient eligibility.
Discover the starting
and
maximum lipase
dose for your
patient
Watch a modern,
peer-guided approach
to
EPI
management
See the science behind
how ZENPEP delivers
more
ZENPEP is $0
for
commercially
insured patients†
ZENPEP is the most widely covered treatment in its
class,
covering 302M individuals
in the United
States1‡
- † This offer is valid only for ZENPEP prescriptions. Eligible patients may pay as little as $0 for their first prescription fill and for refills. Check with pharmacist for copay discount. Maximum savings limit applies; patient out-of-pocket expense may vary. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please see non-CF Patient Support Program Terms, Conditions, and Eligibility Criteria at www.ZENPEPsupport.com.
- ‡ Products are not substitutable. Material differences exist between products. Consult each individual product’s United States Prescribing Information for full details.
ZENPEP delivered a 26%
improvement in mean CFA
compared with
placebo2,4§‖
ZENPEP delivered a
26% improvement in
mean CFA
compared
with
placebo2,4§‖
improvement in mean CFA
compared with placebo2,4§‖
26% improvement in
mean CFA compared
with placebo2,4§‖
- § Normal CFA is defined as >93%.5
- ‖ A randomized, double-blind, placebo-controlled, 2-treatment, crossover study (ZENPEP Study 1) in 34 patients with EPI due to CF aged 7 to 23 years. Patients were randomized to ZENPEP or placebo for 6 to 7 days of treatment, followed by crossover to the alternate treatment for 6 to 7 days. All patients consumed >100 g of fat per day. The primary efficacy endpoint was the mean difference in CFA between ZENPEP and placebo, which was measured from a 72-hour stool collection during both treatments. The use of enzymes other than ZENPEP and drugs affecting gastric pH or motility was not allowed during the trial.
- CFA=coefficient of fat absorption.
